Fang and colleagues have suggested that antihypertensive calcium channel blockers would be useful for COVID-19 patients with cardiac diseases, hypertension, or DM since there is no evidence of ACE2 expression induction with these agents [20]. Here, ACE2 is linked to hypertensive disorder.